Precision Medicine Economics Team
The Manchester Centre for Health Economics (MCHE) is excited to introduce a new research team focussed on the economics of precision medicine within healthcare. The Precision Medicine Economics Team (PMET) comprises researchers and PhD students interested in methodological research related to the valuation and evaluation of new genomic and ‘omic’-based technologies. The team will build upon the collective expertise generated from working on large MRC-funded research projects within stratified medicine at Manchester, such as MATURA (rheumatoid arthritis), MASTERPLANS (lupus) and PSORT (psoriasis), to advance economics research methods in this field.
The current members of MCHE-PMET include:
Professor Katherine Payne who leads PMET and is focused broadly on the economics of genomics and precision medicine with a particular interest on how to value the benefits of genomic interventions and how to conduct cost-effectiveness analyses of precision medicine.
Niall Davison who is using a discrete choice experiment to elicit preferences from clinicians and patients for a new stratified approach to prescribing biologics for treating psoriasis.
Dr. Caroline Vass who is using a discrete choice experiment to elicit preferences from clinicians, patients and the public (in the UK and Sweden) for a new stratified approach to prescribing biologics for treating rheumatoid arthritis.
Anna Donten who is currently undertaking a PhD focused on the stratification of methotrexate treatment for rheumatoid arthritis. Anna is also developing a method of finding the optimal distribution of screens in a stratified screening program using mathematical optimisation.
Martin Eden who is undertaking a PhD that investigates how non-health value from genomic-based diagnostics can be incorporated within economic evaluations.
Sean Gavan who is investigating the cost-effectiveness of monitoring immunogenicity to anti-TNF therapies in rheumatoid arthritis and is involved in developing stratified-based approaches to treating patients with systemic lupus erythematosus as part of the MASTERPLANS  project.
Alex Thompson who has a joint position with the MRC-funded Manchester Molecular Pathology Innovation Centre (MMPathIC) and seeks to provide support to both the commercial sector and to university-led research teams as to how molecular-based diagnostics can be introduced within the NHS.
Stuart Wright who is undertaking a PhD aiming to investigate how capacity constraints can be incorporated into economic evaluations of stratified medicine. The case study for the PhD will focus on the delays in the availability of EGFR and ALK mutation testing following NICE approval of stratified medicines for non-small cell lung cancer.
Dr. Ji-Hee Youn who is working on an NIHR-funded project seeking to examine the effect of competing risks and direct treatment disutility on the cost-effectiveness of interventions for people with multi-morbidity.
Cheryl Jones who is currently researching the economics of presenteeism in the context of rheumatoid arthritis and ankylosing spondylitis. Cheryl is also interested in the role of precision medicine, specifically in the context of rheumatoid arthritis.
Peslie Gibson Ng'ambi who has a joint position with the MRC-funded Manchester Molecular Pathology Innovation Centre (MMPathIC) working on projects such as the economic evaluation of the Ultra-sensitive Cardiac Troponin l (cTnl) for risk-stratification, Rule-out, and therapy guidance.
The MCHE-PMET has been established in line with the strategic direction of The University of Manchester towards the development, evaluation and implementation of precision medicine that includes The Precision Medicine Institute, The Stoller Biomarker Discovery Centre , the Manchester Molecular Pathology Innovation Centre and the Manchester Centre for Genomics Medicine that is actively involved with the 100,000 Genome Project.